-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing
NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
NuCana (NASDAQ:NCNA) stock is surging higher on Wednesday after the company revealed fast track designation from the U.S. Food and Drug Administration (FDA) for Acelarin.
Acelarin is a treatment in development by NuCana for patients suffering from advanced biliary tract cancer. There's currently a Phase III study underway that covers using it as a first-line treatment for this use.
So what does that mean for NCNA stock? Fast track designation is handed out by the FDA to treatments aiming at serious conditions or unmet medical needs. With it, the review process of a drug can go much fast, which means getting to market sooner.
- 7 Risk-Averse Stocks to Buy for a Fortified Portfolio
Hugh Griffith, founder and CEO of NuCana, said this in the press release boosting NCNA stock higher today.
"We recently announced enrollment of 418 evaluable patients in our Phase III study, which is expected to enable the first interim analysis in the first half of 2022. This has the potential to allow for an accelerated approval of a new drug application (NDA) for Acelarin in the United States. With both Fast Track and Orphan Drug designations in place, we look forward to working closely with the FDA in our efforts to gain approval for Acelarin as the first approved front-line treatment option for patients with biliary tract cancer."
NCNA stock is seeing heavy trading on today's FDA news. As of this writing, some 78 million shares have changed hands. For perspective, the company's daily average trading volume is around 357,000 shares.
There's more stock market news to dive into below!
We've got all the latest coverage that traders need to know about today. Among that is what's affecting Meta Materials (NASDAQ:MMAT), SoFi (NASDAQ:SOFI), and Helbiz (NASDAQ:HLBZ) shares today. You can learn all about those stocks at the following links!
More Wednesday Stock Market News
- MMAT Stock: 9 Things to Know About the Latest Meta Materials Merger
- SOFI Stock: Why Is Reddit Favorite SoFi Stumbling Today?
- HLBZ Stock: Why Is Red-Hot Helbiz Plunging Today?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That's because these "penny stocks" are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com's writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
The post NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing appeared first on InvestorPlace.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股市新聞、股票諮詢和交易提示
NuCana (NASDAQ:NCNA) stock is surging higher on Wednesday after the company revealed fast track designation from the U.S. Food and Drug Administration (FDA) for Acelarin.
努卡納納斯達克股票代碼:NCNA)週三股價飆升,此前該公司公佈了美國食品和藥物管理局(FDA)對Acelarin的快車道指定。
Acelarin is a treatment in development by NuCana for patients suffering from advanced biliary tract cancer. There's currently a Phase III study underway that covers using it as a first-line treatment for this use.
Acelarin是NuCana公司正在開發的一種治療晚期膽道癌患者的藥物。目前有一項第三階段的研究正在進行中,該研究涵蓋了將其作為這種用途的一線治療方法。
So what does that mean for NCNA stock? Fast track designation is handed out by the FDA to treatments aiming at serious conditions or unmet medical needs. With it, the review process of a drug can go much fast, which means getting to market sooner.
那麼,這對新華社的股票意味着什麼?快速通道指定是由FDA頒發給針對嚴重疾病或未得到滿足的醫療需求的治療。有了它,藥物的審查過程可以快得多,這意味着更快地進入市場。
- 7 Risk-Averse Stocks to Buy for a Fortified Portfolio
- 為強化投資組合買入7只規避風險的股票
Hugh Griffith, founder and CEO of NuCana, said this in the press release boosting NCNA stock higher today.
NuCana創始人兼首席執行官休·格里菲斯(Hugh Griffith)在新聞稿中説了這番話,推動NCNA股價今天走高。
"We recently announced enrollment of 418 evaluable patients in our Phase III study, which is expected to enable the first interim analysis in the first half of 2022. This has the potential to allow for an accelerated approval of a new drug application (NDA) for Acelarin in the United States. With both Fast Track and Orphan Drug designations in place, we look forward to working closely with the FDA in our efforts to gain approval for Acelarin as the first approved front-line treatment option for patients with biliary tract cancer."
我們最近宣佈在我們的第三階段研究中招募418名可評估的患者,預計將在2022年上半年進行第一次中期分析。這有可能加速批准Acelarin在美國的新葯申請(NDA)。隨着Fast Track和孤兒藥物指定的到位,我們期待着與FDA密切合作,努力獲得批准,將Acelarin作為膽道癌患者的第一個批准的一線治療方案。“
NCNA stock is seeing heavy trading on today's FDA news. As of this writing, some 78 million shares have changed hands. For perspective, the company's daily average trading volume is around 357,000 shares.
今天FDA的新聞讓NCNA的股票交易火爆。截至撰寫本文時,已有約7800萬股易手。相比之下,該公司的日均交易量約為35.7萬股。
There's more stock market news to dive into below!
下面有更多的股市新聞值得一探!
We've got all the latest coverage that traders need to know about today. Among that is what's affecting Meta Materials (NASDAQ:MMAT), SoFi (NASDAQ:SOFI), and Helbiz (NASDAQ:HLBZ) shares today. You can learn all about those stocks at the following links!
今天交易員需要了解的最新消息我們都有。在這其中,有一點是有影響的元材料(納斯達克股票代碼:MMAT)SOFI(納斯達克:SOFI),以及赫爾比茲(納斯達克股票代碼:HLBZ)今天的股票。你可以在下面的鏈接上了解所有關於這些股票的信息!
More Wednesday Stock Market News
更多週三股市新聞
- MMAT Stock: 9 Things to Know About the Latest Meta Materials Merger
- SOFI Stock: Why Is Reddit Favorite SoFi Stumbling Today?
- HLBZ Stock: Why Is Red-Hot Helbiz Plunging Today?
- MMAT股票:關於最新的Meta Material合併需要知道的9件事
- 索菲股票:為什麼Reddit最受歡迎的SoFi今天步履蹣跚?
- HLBZ股票:為什麼紅火的Helbiz今天暴跌?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
在出版之日,威廉·懷特沒有(直接或間接)持有本文所述證券的任何頭寸。本文表達的觀點是作者的觀點,以InvestorPlace.com為準出版指南.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That's because these "penny stocks" are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com's writers disclose this fact and warn readers of the risks.
除了最罕見的例外,InvestorPlace不會發布關於市值低於1億美元或每天交易量低於10萬股的公司的評論。這是因為這些“廉價股”經常是詐騙藝術家和市場操縱者的遊樂場。如果我們對可能受我們的評論影響的低成交量股票發表評論,我們要求 InvestorPlace.com該書的作者披露了這一事實,並警告讀者其中的風險。
Read More: Penny Stocks — How to Profit Without Getting Scammed
閲讀更多信息: 細價股-如何在不上當的情況下獲利
The post NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing appeared first on InvestorPlace.
NCNA股票:大型抗癌藥物新聞讓NuCana暴漲的帖子首先出現在InvestorPlace上。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧